Time Europe Interviews Former President Clinton About Deal to Cut Prices of Generic AIDS Drugs in Africa, Caribbean
November 3, 2003
The Nov. 3 issue of TIME Europe featured an interview with former President Bill Clinton about his foundation's recently announced program to secure antiretroviral drugs from generic drug manufacturers at discounted prices and to implement nationwide treatment plans in four African and more than 12 Caribbean nations (Pooley, TIME Europe, 11/3). The William J. Clinton Presidential Foundation HIV/AIDS Initiative last month secured a deal with Indian generic drug manufacturers Ranbaxy Laboratories, Cipla and Matrix Laboratories and South Africa's Aspen Pharmacare that will reduce the cost of commonly used three-drug regimens to 38 cents per patient per day, down from the already discounted price of 55 cents per patient per day; the lowest available price of the same three-drug regimen using brand-name antiretrovirals is $1.54 per patient per day. In addition to reducing the cost of the three-drug antiretroviral regimen, the deal will reduce by half the cost of the antiretroviral drug nevirapine for people in developing nations. The initial pricing agreement covers drugs used in two common, three-drug regimens: stavudine, lamivudine and nevirapine; and zidovudine, lamivudine and nevirapine (Kaiser Daily HIV/AIDS Report, 10/24).
"Dangerous, Wildly Inaccurate" List of NIH Researchers Under Scrutiny Threatens Science, New York Times Columnist Says
Dried Blood CD4+ T-Cell Test May be Cheaper, More Convenient Alternative in Developing Countries, Study Says
This article was provided by Henry J. Kaiser Family Foundation. It is a part of the publication Kaiser Daily HIV/AIDS Report. Visit the Kaiser Family Foundation's website to find out more about their activities, publications and services.